2025-06-01T00:00:00.000+01:00
Ongoing

Elevate Study

Elevate Study
Chronic Lymphocytic Leukaemia

A multicentre, open-label, randomised, phase IV study to investigate acalabrutinib monotherapy compared to investigator’s choice of treatment in adults (> 18 years) with chronic lymphocytic leukaemia and moderate to severe cardiac impairment.

A multicentre, open-label, randomised, phase IV study to investigate acalabrutinib monotherapy compared to investigator’s choice of treatment in adults (> 18 years) with chronic lymphocytic leukaemia and moderate to severe cardiac impairment.

Trial overview

Disease

Haematology

Topic

Diagnostics

Sponsor

Astra Zeneca

Description

A multicentre, open-label, randomised, phase IV study to investigate acalabrutinib monotherapy compared to investigator’s choice of treatment in adults (> 18 years) with chronic lymphocytic leukaemia and moderate to severe cardiac impairment.

Study details

For detailed information on this trial, please click here

Trial status

Open and recruiting June 2025

Location

Oxford :::

Principal Investigator

Dr Toby Eyre

MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD (University of Newcastle)

Consultant Haematologist

Oxford